Drug intelligence / Profile preview

avian influenza vaccine

Development stage: Preclinical
Lead developer: SK bioscience
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular, Subcutaneous, Intratracheal, Conjunctival, In Ovo

Overview

This avian influenza vaccine is a collaborative development project between Sanofi and SK Bioscience aimed at creating a vaccine to protect against highly pathogenic avian influenza strains, such as H5N1. The vaccine is intended for pandemic preparedness, designed to elicit a robust immune response against the viral hemagglutinin protein to prevent infection and transmission. As of the current reporting, the candidate is in the preclinical stage of development, leveraging the combined vaccine manufacturing and R&D expertise of both companies.

Other names: avian flu vaccineH5N1 vaccineH-5N1 vaccineH 5N1 vaccine

Targets

HA (Hemagglutinin)

Beyond the preview

Go deeper on avian influenza vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on avian influenza vaccine.

Explore the full profile